ECB dove says rate hike may come during the third quarter

ECB dove says rate hike may come during the third quarter


European Central Bank Governing Council member Ignazio Visco has added his voice to heated discussions on when the ECB will begin to raise its benchmark interest rate.

Rates in the euro zone have been negative following the region’s sovereign debt crisis, and the ECB has confirmed that it will conclude its net asset purchases in the third quarter — opening up the possibility of a rate hike.

Some market participants are anticipating a July rate hike, with reports than more hawkish members of the ECB are keen to raise rates sooner rather than later.

Visco, the governor of the Bank of Italy and a notable “dove” — who tend to favor more supportive monetary policy — told CNBC Thursday that it’s “very likely” asset purchases will end in June, leading to the issue of what to do with rates.

“We said that they will be adjusted sometime after the end of the purchasing program; now this sometime has to be defined, we have to look at the developments, it may be during the third quarter or at the end of the year, but it has to be gradual,” he said.

“As we said there are three main conditions that we are looking for: the first is gradualism, the second is optionality and the third, we have to guarantee smooth functioning of financial markets that these flexibility is necessary.”



Source

Investors are misreading news about the Iran war, analysts say as markets whipsaw
World

Investors are misreading news about the Iran war, analysts say as markets whipsaw

An Iranian flag flutters as a woman walks past damaged buildings amid a 10-day ceasefire between Lebanon and Israel, in the southern suburbs of Beirut, Lebanon, April 20, 2026. Marko Djurica | Reuters “Complacent” investors risk getting wrong-footed as they continue to misread developments in the Iran war, analysts said after markets reacted to the […]

Read More
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to  billion
World

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike Blake | Reuters Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday. Lilly will pay $3.25 billion upfront, and the remaining payments are contingent upon clinical, […]

Read More
USA Rare Earth to buy Brazil’s Serra Verde for .8 billion to build supply outside Asia
World

USA Rare Earth to buy Brazil’s Serra Verde for $2.8 billion to build supply outside Asia

USA Rare Earth has announced plans to buy Brazilian rare earths miner Serra Verde in a deal worth $2.8 billion in cash and shares, as it seeks to challenge China’s dominance of the supply chain. The Oklahoma-headquartered company said it will pay $300 million in cash and $126.9 million in its own newly issued stock […]

Read More